Study wrapper · #1100
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
Mohamed ZI, Shidane AA, Abdiasis AM, et al. Endocrinology, diabetes & metabolism. 2026.
DOI: 10.1002/edm2.70298PubMed: 42533465
Editor's note
A synthesis of trial and mechanistic evidence positioning tirzepatide within obesity-related HFpEF management, drawing on the SUMMIT trial's reported effects on weight, epicardial fat, and symptom scores. The authors are careful to note that cross-agent comparisons and combination therapy remain unproven in dedicated trials.
Plain-language abstract
This review synthesizes evidence on tirzepatide and SGLT2 inhibitors for obesity-related heart failure with preserved ejection fraction, noting tirzepatide's substantial weight loss and symptom improvement in the SUMMIT trial. The authors caution that combined use has not yet been tested in a dedicated trial.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026